Joel Lippman, MD

Noven Pharmaceuticals, Inc.
Papers:
Safety and Efficacy of Low-dose Mesylate Salt of Paroxetine (LDMP) for the Treatment of Vasomotor Symptoms (VMS) Due to Menopause: Pooled Results From Two Randomized, Placebo-controlled Phase 3 Studies